You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid intercalator removal from size-selected DNA for next generation sequencing

    SBC: DIFFINITY GENOMICS, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Information from next generation sequencing is widely used in translational studies and promises to be a cornerstone of personalized medicine where therapeutic courses are linked to an individual's genetic makeup. Extraction of DNA from gels following electrophoresis to obtain size-selected DNA fragments is a labor intensive part of library preparation ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It accounts for 3.5% of all malignancies in children. Despite multimodality therapeutic treatment approaches, the outlook for patients with metastatic subtype, alveolar rhabdomyosarcoma (ARMS), remains unchange ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. A Force-controlled Probe Based Platform for Single Cell Biomolecular Delivery

    SBC: INFINITESIMAL, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Application of nanotechnology in medicine, nanomedicine, has provided numerous emerging opportunities in healthcare, particularly given ever increasing demand for in vitro toxicology and diagnostics towards personalized medicine. With increasing demand for personalized medicine, pharmaceutical companies strive in taking advantage of the potential of nan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Alafair Biosciences develops cross-linked polysaccharide hydrogel films to addres

    SBC: ALAFAIR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): The goal of this STTR project is to develop a pre-formed, naturally-based hydrogel postoperative adhesion barrier with improved handling characteristics, laparoscopic deliverability, and consistent efficacy. Our technology is based on a novel, patented process that imparts exceptional elasticity and toughness on normally brittle, weak materials. Postoperative a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Feasibility of Pediatric Contrast Sensitivity Test

    SBC: Precision Vision, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): This STTR project develops and assesses a new clinical test of visual contrast sensitivity that will work on infants and uninstructable children nd adults. This Stripe Card Contrast Sensitivity (SCCS) test would be useful in quantitatively describing the visual function of patients with a range of visual disorders, in planning and following treatments and inter ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Microbial Surrogate Assay for Environmental PAH Exposure

    SBC: ARPHION LTD            Topic: NIEHS

    DESCRIPTION (provided by applicant): Arphion is a company established to develop noninvasive products that will be used to diagnose, prevent, and treat head and neck and other cancers. 41,000 people are diagnosed with head and neck cancer (HNC) every yearin the United States, with 8,000 deaths. Tens of millions of people in the US are at increased risk for HNC due to exposure to the polycyclic ary ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. High Throughput Manufacturing of Monodispersed Nanoparticles for Biomedicine

    SBC: CHEMTOR, L.P.            Topic: NIA

    DESCRIPTION (provided by applicant): This Phase I Small Business Technology Transfer (STTR) project focuses on the development of a new platform manufacturing process for large-scale preparation of monodispersed polymeric nanoparticles (NPs) suitable for biomedical applications through the use of a large-scale fiber fluidic system. Although laboratory processes for reproducible synthesis of polyme ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Pharmacotherapeutic Bioadhesive Patch for Oral Ulcerations

    SBC: POST OAK PHARMACEUTICALS, INC.            Topic: NIDCR

    Project Summary Oral ulceration is one of the most commonly encountered oral diseases, with an estimated prevalence of 4% in the USA. Managing large or multiple ulcers that are caused by diseases of unknown etiology, such as erosive lichen planus or aphthous ulcers which affect 25% of the population worldwide, is also a challenge to dentists and specialists. Ulceration of the oral mucosa can caus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel drug VS-105 for treatment of diabetic nephropathy

    SBC: Vidasym, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Diabetes is by far the leading cause of CKD (diabetic nephropathy), accounting for 44% of new cases of dialysis (in 2005). Current treatments including ACE inhibitors for CKD patients mainly focus on managing symptoms and disease complications. Despite the various treatments available, the ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government